| HCV broadly neutralizing antibodies use a CDRH3 disulfide motif to recognize an E2 glycoprotein site that can be targeted for vaccine design AI Flyak, S Ruiz, MD Colbert, T Luong, JE Crowe, JR Bailey, PJ Bjorkman Cell host & microbe 24 (5), 703-716. e3, 2018 | 108 | 2018 |
| Broadly neutralizing antibodies targeting new sites of vulnerability in hepatitis C virus E1E2 MD Colbert, AI Flyak, CO Ogega, VJ Kinchen, G Massaccesi, ... Journal of virology 93 (14), 10.1128/jvi. 02070-18, 2019 | 47 | 2019 |
| Plasma deconvolution identifies broadly neutralizing antibodies associated with hepatitis C virus clearance VJ Kinchen, G Massaccesi, AI Flyak, MC Mankowski, MD Colbert, ... The Journal of Clinical Investigation 129 (11), 4786-4796, 2019 | 39 | 2019 |
| Association of Cardiovascular Disease in Patients with Mycosis Fungoides and Sézary Syndrome Compared to a Matched Control Cohort CM Johnson, SM Talluru, B Bubic, M Colbert, P Kumar, H Tsai, ... JID Innovations 3 (6), 100219, 2023 | 1 | 2023 |
| Interface dermatitis: Delineating the diagnosis with adaptive immune markers EN Brooks, MD Colbert, IB Sander Journal of cutaneous pathology 49 (7), 669, 2022 | | 2022 |
| Broadly neutralizing antibodies against HCV use a CDRH3 disulfide motif to recognize an E2 glycoprotein site that can be targeted for vaccine design AI Flyak, S Ruiz, M Colbert, T Luong, JE Crowe Jr, JR Bailey, PJ Bjorkman CANCER IMMUNOLOGY RESEARCH 7 (2), 2019 | | 2019 |
| MD 21287, USA. Email: ibrauns2@ jhmi. edu EN Brooks, MD Colbert, IB Sander therapy 43 (4), 339-346, 2016 | | 2016 |
